Datroway (datopotamab deruxtecan-dlnk) — Medical Drug Clinical Criteria
Customize your policy alerts
Sign up for Anthem Policy CC-0279 alerts
Get alerted when Policy CC-0279 changes without checking for updates manually.
Monitor payer policy activity
Clinical criteria governing prior authorization and medical necessity determinations for Datroway for adults with unresectable or metastatic HR-positive, HER2-negative breast cancer and for certain EGFR‑mutated NSCLC patients; affects providers seeking coverage under Anthem medical benefit plans.
Added FDA indication for use in EGFR-mutated NSCLC in locally advanced or metastatic disease in those with prior EGFR and platinum based chemotherapy.
Wording and formatting criteria changes during annual review.
Coding update replacing prior HCPCS/NOC codes and consolidating to J9011 as the HCPCS code for Datroway.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.